AnaptysBio Wins Court Ruling Against Tesaro, Preserving Jemperli Royalties

The Delaware Chancery Court dismissed Tesaro's anticipatory breach of contract claim against AnaptysBio, affirming Anaptys's position that it never repudiated the Collaboration Agreement for Jemperli. This ruling preserves Anaptys's current contracted royalty rates and rejects Tesaro's request for any royalty reduction. AnaptysBio continues to pursue its claims that Tesaro/GSK materially breached the agreement, including seeking reversion of Jemperli, with a trial scheduled for July 14-17, 2026.